A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection

Trial Profile

A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 29 May 2017 Planned End Date changed from 18 Jan 2021 to 20 Dec 2021.
    • 29 May 2017 Planned primary completion date changed from 5 Mar 2019 to 4 Feb 2020.
    • 07 Apr 2017 Planned initiation date changed from 1 May 2017 to 28 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top